article · Cureus
Post-treatment surveillance for renal cell carcinoma varies considerably across healthcare institutions following nephrectomy or ablation procedures. Although regular monitoring is essential to catch local recurrence, metastasis, and complications, current practices differ widely regarding imaging modalities, visit frequency, and follow-up duration. Established guidelines from major clinical bodies are largely risk-stratified and lack strong comparative evidence. While advanced imaging techniques such as multiparametric magnetic resonance imaging and contrast-enhanced computed tomography are proposed to aid early detection, their cost-effectiveness and long-term outcomes remain uncertain. Furthermore, minimally invasive ablative therapies introduce distinct recurrence patterns that complicate standardised follow-up. An analysis of five qualifying studies, selected from an initial pool of 170 records, confirms significant heterogeneity across follow-up schedules and patient risk-stratification methods, highlighting a pressing need to harmonise post-treatment surveillance protocols.
Kidney cancer survivors require reliable follow-up to detect recurring disease early. When clinics use conflicting monitoring schedules and imaging tools, patients may face inconsistent care, missed recurrences, or unnecessary medical tests. Harmonising these guidelines helps standardise long-term recovery and ensures imaging resources are used effectively.
The findings highlight an opportunity for medical software developers and clinical imaging providers to design standardised follow-up protocols or decision-support tools for oncology departments. These could assist clinicians in managing post-ablation and post-nephrectomy monitoring. However, the abstract indicates that the underlying comparative and cost-effectiveness evidence is still incomplete, meaning such tools remain at an early, guideline-formation stage rather than near deployment.
AI-generated from the published abstract. Always read the original work before citing.
Guidelines and surveillance practices after nephrectomy or renal cell carcinoma (RCC) ablation are very diverse across institutions. It has been proven that close follow-up is essential to identify local recurrence, metastatic spread, and treatment-related complications, but the frequency, length, and imaging modalities employed in surveillance are widely different in terms of practices. Although these guidelines have been advised by larger organizations like the American Urological Association (AUA) and the European Society for Medical Oncology (ESMO), they are mostly risk-stratified and lack comparative data. Entirely new imaging methods (such as multiparametric MRI and state-of-the-art contrast-enhanced CT) have been proposed to enhance early disease diagnosis and are currently under consideration regarding their cost-effectiveness and long-term results. Simultaneously, some minimally invasive ablative forms of treatment, such as radiofrequency and cryoablation, have complicated surveillance measures, given that recurrence patterns differ from those seen after conventional nephrectomy. Although systematic reviews have found the oncological safety of active surveillance in specific small kidney masses, research still shows loopholes regarding regular follow-up and outcome reporting that is patient-centered. Out of 170 records initially identified, 140 unique articles were screened after duplicate removal, with 30 assessed in full text. Following exclusions, five studies were finally included in the review. These comprised a mixture of clinical guidelines, systematic reviews, and observational studies, highlighting the heterogeneity of follow-up schedules, imaging-based approaches, and patient risk stratification. This scoping review maps the existing literature on surveillance following nephrectomy or ablation in RCC. The review establishes differences in practice, evidence, and research gaps that need to be harmonized to enhance long-term management.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.7759/cureus.97554
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
